ProQR Therapeutics, a preclinical Dutch biotech that is developing an mRNA repair therapy for cystic fibrosis, raised $98 million by offering 7.5 million shares (upsized from 6.3 million) at $13, the high end of the $11-$13 range. Insiders, including Sofinnova and Fidelity, planned to purchase 1.6 million shares. ProQR Therapeutics plans to list on the NASDAQ under the symbol PRQR. ProQR Therapeutics initially filed confidentially on 7/11/2014. Leerink Partners and Deutsche Bank acted as lead managers on the deal.
